Date: 2015-05-19
Type of
information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: abemaciclib (LY2835219)
Action
mechanism:
- cell cycle inhibitor/cyclin dependant kinase inhibitor. Abemaciclib (LY2835219) is a cell cycle inhibitor, designed to block the growth of cancer cells by specifically inhibiting CDK 4 and 6. Although abemaciclib inhibits both CDK 4 and CDK 6, the results from the cell-free enzymatic assays have shown that it was most active against Cyclin D 1 and CDK 4.
Disease: non-small cell lung cancer (NSCLC)
Therapeutic
area: Cancer - Oncology
Country: Australia, France, Germany, Hungary, Italy, Republic of Korea, Poland, Romania, Russian Federation, Spain, Taiwan, Ukraine, USA
Trial
details:
- The main purpose of this study is to evaluate the effectiveness of abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. (NCT02450539)
Latest
news:
- • On May 19, 2015, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov for abemaciclib (LY2835219) and is currently recruiting participants.
Is
general: Yes
